Nadine Beauger, panellist at the Strategic Forum an initiative of the CCMM

On Monday, December 13, Nadine Beauger, IRICoR’s President and CEO, took part in the panel discussion: Leveraging our niches of excellence, along with Stéphane Létourneau, Executive Vice President at Mila, and Stéphane Paquet, President and CEO at Montréal International. This panel was presented as part of the Strategic Forum: The pharmaceutical industry: At the forefront of life sciences, an initiative […]


Martinsried, Germany and Montréal, Canada – Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, IRICoR, and the University of Montréal (Université de Montréal, UdeM) expand their mutual analyses of potentially novel cancer antigens.
In January 2020, Medigene entered into a research collaboration on novel cancer antigens for highly specific immunotherapies […]

Nadine Beauger, Panellist at the CSPC Conference

On November 22nd, Nadine Beauger, President and Chief Executive Officer of IRICoR, was invited as a panellist at the 13th Canadian Science Policy Conference, presented by the Canadian Science Policy Centre (CSPC). For this occasion, Nadine participated in the session “Realizing Canada’s Life Sciences Opportunities,” moderated by Gordon C. McCauley, President & CEO of adMare BioInnovations, along with Cate Murray, […]

LeadAction Ovarian Cancer Competition – a look back at research projects

In 2020, IRICoR concluded a major partnership with Ovarian Cancer Canada. By launching the pan-Canadian LeadAction Ovarian Cancer Competition, the 5th call for projects at IRICoR, these organizations aimed to fund innovative ovarian cancer research projects to accelerate the discovery of new treatments.
A few months ago, the winners of the Competition were announced. A total amount of $2.3M over two (2) years […]

IRICoR welcomes the Quebec government’s new initiative

IRICoR is delighted by the commitment made by the ministère de l’Économie et de l’Innovation (MEI) in creating “Médicament Québec”, a major strategic hub whose mission is to promote greater autonomy and increase Quebec’s drive in drug discovery, development and production.
This large-scale project led by Université de Montréal, and got off the ground thanks to $13M in funding from the MEI. Through […]

IRICoR welcomes the appointment of Nadine Beauger as a member of the Board of Directors of BIOQuébec

At a recent special evening to mark the 30th anniversary of BIOQuébec, the organization welcomed the appointment of three new members to its board of directors. IRICoR is therefore pleased to announce the appointment of its President and CEO, Ms. Nadine Beauger, to the Board of Directors of BIOQuébec.
BIOQuébec is the largest Quebec network in biotechnology and life sciences. The […]

A new research partnership is proving that pooling Canadian innovation efforts can lead to breakthrough discoveries

The Alberta-based Canadian Glycomics Network (GlycoNet), which develops new carbohydrate-based drugs, vaccines and diagnostics, joined forces with Quebec-based IRICoR, a group that specializes in drug discovery and commercialization. Both are part of Canada’s Networks of Centres of Excellence program, which fosters academic, government and industry partnerships […]

IRICoR will participate in the next BIO Digital conference

IRICoR announces its participation in the 2nd edition of the BIO Digital conference to be held on June 10-11 and June 14-18, 2021. This industry event aims to create business opportunities among life science players from all over the world. It is also an opportunity for companies and institutions to develop partnerships of interest with complementary organizations, in particular through […]

IRICoR congratulates Dr. Rénaldo Batista on his appointment to the National Order of Quebec

Dr Rénaldo Bastista will be decorated, on June 22, with the title of Officer of the National Order of Quebec, on the occasion of the 35th ceremony of this illustrious organization.
Dr. Rénaldo Batista, CEO of the Oncopole, is one of the 43 exceptional people who will be honored this year with one of the three degrees of the National Order […]

Identification of ten novel tumor-specific antigens immunogenic for T cells

Martinsried/Munich and Montréal, 10 April 2021. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today presents the screening and identification of novel immunogenic tumor-specific antigens (TSAs) derived from non-coding regions of the human genome at the American Association for Cancer Research Virtual Annual Meeting (AACR) 2021. The […]

« Previous Page | Next Page »

© 2008-2022 IRICoR